Helicon Group Limited (ASX: HCG) of Australia received SFDA approval for ReCell®, a skin regeneration concept and device. Before the device can be imported to China, however, Helicon and the SFDA must resolve some importation issues because the device contains trypsin. ReCell treats burns and small wounds. It can also be used for cosmetic surgery, repairing scars. The device harvests a patient’s own skin cells to treat the wounds, improving the color match with a patient’s skin and eliminating tissue rejection. More details...